600267.SH
Zhejiang Hisun Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 13.32
−2.06%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.3B | 10.5B | 10.3B | 10.1B | 11.4B |
| Cost of Revenue | 5.5B | 5.8B | 6.0B | 5.9B | 6.3B |
| Gross Profit | 4.8B | 4.7B | 4.4B | 4.2B | 5.0B |
| Operating Expenses | |||||
| R&D Expense | 520.5M | 478.5M | 357.7M | 392.0M | 428.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 866.1M | 872.5M | 897.0M | 908.7M | 1.1B |
| Selling & Marketing Expense | 2.1B | 2.1B | 2.1B | 2.4B | 2.4B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 3.7B | 3.6B | 3.6B | 3.9B | 4.3B |
| Cost and Expenses | 9.2B | 9.5B | 9.6B | 9.8B | 10.6B |
| Operating Income (EBIT) | 1.1B | 867.0M | 721.3M | 89.4M | 682.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.0B | 815.4M | 718.1M | (82.9M) | 683.4M |
| Income Tax Expense | 339.2M | 267.9M | 126.8M | 14.1M | 192.2M |
| Bottom Line | |||||
| Net Income | 702.2M | 540.7M | 601.2M | (93.2M) | 488.9M |
| Earnings from Cont. Ops | 709.2M | 547.5M | 591.3M | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 702.2M | 540.7M | 601.2M | (93.2M) | 488.9M |
| Per Share | |||||
| Basic EPS | CN¥0.61 | CN¥0.46 | CN¥0.52 | — | — |
| Diluted EPS | CN¥0.61 | CN¥0.46 | CN¥0.52 | — | — |
| Revenue Per Share | CN¥8.98 | CN¥8.97 | CN¥8.94 | — | — |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 1.2B | 1.2B | — | — |
| Diluted Shares Outstanding | 1.1B | 1.2B | 1.2B | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 1.8B | 1.8B | 1.1B | 1.7B |
| D&A | — | 962.4M | 1.1B | 1.0B | 1.0B |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026